Literature DB >> 28539219

Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors.

Zhen Fang1, Tian-Qi Wang2, Hui Li1, Guo Zhang3, Xiao-Ai Wu1, Li Yang1, Yu-Lan Peng1, Jun Zou1, Lin-Li Li3, Rong Xiang4, Sheng-Yong Yang5.   

Abstract

Herein we report the discovery of a series of new small molecule inhibitors of histone lysine demethylase 4D (KDM4D). Molecular docking was first performed to screen for new KDM4D inhibitors from various chemical databases. Two hit compounds were retrieved. Further structural optimization and structure-activity relationship (SAR) analysis were carried out to the more selective one, compound 2, which led to the discovery of several new KDM4D inhibitors. Among them, compound 10r is the most potent one with an IC50 value of 0.41±0.03μM against KDM4D. Overall, compound 10r could be taken as a good lead compound for further studies.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Epigenetics; Histone lysine demethylase; KDM4D; Small molecule inhibitor; Structure-activity relationship

Mesh:

Substances:

Year:  2017        PMID: 28539219     DOI: 10.1016/j.bmcl.2017.05.002

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

Review 1.  Recent Advances with KDM4 Inhibitors and Potential Applications.

Authors:  Qiong Wu; Brandon Young; Yan Wang; Andrew M Davidoff; Zoran Rankovic; Jun Yang
Journal:  J Med Chem       Date:  2022-07-15       Impact factor: 8.039

Review 2.  Histone Demethylase JMJD2D: A Novel Player in Colorectal and Hepatocellular Cancers.

Authors:  Qiang Chen; Kesong Peng; Pingli Mo; Chundong Yu
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

3.  Small molecule KDM4s inhibitors as anti-cancer agents.

Authors:  Hongzhi Lin; Qihang Li; Qi Li; Jie Zhu; Kai Gu; Xueyang Jiang; Qianqian Hu; Feng Feng; Wei Qu; Yao Chen; Haopeng Sun
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

4.  Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer.

Authors:  Heng Zheng; Yan Tie; Zhen Fang; Xiaoai Wu; Tao Yi; Shuang Huang; Xiao Liang; Yanping Qian; Xi Wang; Ruyu Pi; Siyuan Chen; Yong Peng; Shengyong Yang; Xia Zhao; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-07-26

5.  Efficient Access to 3,5-Disubstituted 7-(Trifluoromethyl)pyrazolo[1,5-a]pyrimidines Involving SNAr and Suzuki Cross-Coupling Reactions.

Authors:  Badr Jismy; Abdellatif Tikad; Mohamed Akssira; Gérald Guillaumet; Mohamed Abarbri
Journal:  Molecules       Date:  2020-04-28       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.